Lidiya Konstantinovna Trepitaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lidiya Konstantinovna Trepitaki has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Irina Viktorovna Kaplieva
Rostov Research Institute of Oncology
60 shared publications - Elena Mikhaylovna Frantsiyants
National Medical Research Center of Oncology, Ministry of Health of Russia
57 shared publications - Ekaterina Igorevna Surikova
National Medical Research Centre for Oncology Rostov-on-Don, Russian Federation
41 shared publications - Irina Valer'EVna Neskubina
National Medical Research Center of Oncology, Ministry of Health of Russia
41 shared publications - Valeriya Akhtyamovna Bandovkina
National Medical Research Center of Oncology, Ministry of Health of Russia
39 shared publications - Natal'YA Dmitrievna Cheryarina
National Medical Research Center of Oncology, Ministry of Health of Russia
24 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (3) , 49-66
Morphological characteristics of An3Ca endometrioid carcinoma and visceral organs in female nude mice with experimental diabetes mellitus
Purpose of the study . To investigate the morphological features of induced An3Ca endometrioid carcinoma and visceral organs in BALB/c nude mice under conditions of diabetes mellitus. Materials and methods . Female BALB/c nude mice weighing 25 ± 2.5 g were used to model uterine tumor growth under conditions of diabetes mellitus. The animals were divided into two experimental groups: group 1 (control) – intrauterine growth of endometrioid carcinoma (n = 5); group 2 (study group) – intrauterine growth of endometrioid carcinoma in the presence of diabetes mellitus (n = 5). Sections of the tumor nodules and organs (uterus, ovaries, liver, lungs, thyroid gland, adrenal glands, and pancreas) were examined microscopically, with images captured using a digital camera. Results . Tumor growth without alloxan administration resulted in the formation of a single tumor nodule in the right uterine horn, with preservation of the main morphological features of its architecture. In contrast, alloxan administration was associated with the formation of a tumor consisting of several separate nodules that completely obliterated the structure of the right ovary and replaced it with tumor tissue. Metastatic involvement of the liver accompanied by vascular congestion of the parenchyma was observed. In the lungs, destruction of the alveolar and bronchial structures was accompanied by vascular congestion, foci of hemorrhage, mucus accumulation in the airway lumens, and the presence of tumor cells. Marked thickening of the colloid was observed throughout the thyroid follicles. Involutional changes were noted in the X-zone and zona glomerulosa of the adrenal cortex, with focal expansion of the zona fasciculata. Diabetes modeling resulted in almost complete loss of the exocrine pancreatic parenchyma, exposing the stromal framework of the organ. Its morphological identity could be established only from isolated small areas of degeneratively altered acini and rare remnants of the islets of Langerhans. Conclusion . In the experimental bimodal model combining two pathological processes, cancer and diabetes mellitus, morphological evidence of mutually reinforcing mechanisms of adverse systemic effects involving multiple organs was observed. This pronounced synergistic effect was manifested by stimulation of tumor progression and pathological changes in visceral organs, expanding our understanding of cancer pathogenesis in the presence of comorbid disease.
- 20 September 2026
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 13 (3) , 49-66
Open AccessMorphological characteristics of An3Ca endometrioid carcinoma and visceral organs in female nude mice with experimental diabetes mellitus
Purpose of the study . To investigate the morphological features of induced An3Ca endometrioid carcinoma and visceral organs in BALB/c nude mice under conditions of diabetes mellitus. Materials and methods . Female BALB/c nude mice weighing 25 ± 2.5 g were used to model uterine tumor growth under conditions of diabetes mellitus. The animals were divided into two experimental groups: group 1 (control) – intrauterine growth of endometrioid carcinoma (n = 5); group 2 (study group) – intrauterine growth of endometrioid carcinoma in the presence of diabetes mellitus (n = 5). Sections of the tumor nodules and organs (uterus, ovaries, liver, lungs, thyroid gland, adrenal glands, and pancreas) were examined microscopically, with images captured using a digital camera. Results . Tumor growth without alloxan administration resulted in the formation of a single tumor nodule in the right uterine horn, with preservation of the main morphological features of its architecture. In contrast, alloxan administration was associated with the formation of a tumor consisting of several separate nodules that completely obliterated the structure of the right ovary and replaced it with tumor tissue. Metastatic involvement of the liver accompanied by vascular congestion of the parenchyma was observed. In the lungs, destruction of the alveolar and bronchial structures was accompanied by vascular congestion, foci of hemorrhage, mucus accumulation in the airway lumens, and the presence of tumor cells. Marked thickening of the colloid was observed throughout the thyroid follicles. Involutional changes were noted in the X-zone and zona glomerulosa of the adrenal cortex, with focal expansion of the zona fasciculata. Diabetes modeling resulted in almost complete loss of the exocrine pancreatic parenchyma, exposing the stromal framework of the organ. Its morphological identity could be established only from isolated small areas of degeneratively altered acini and rare remnants of the islets of Langerhans. Conclusion . In the experimental bimodal model combining two pathological processes, cancer and diabetes mellitus, morphological evidence of mutually reinforcing mechanisms of adverse systemic effects involving multiple organs was observed. This pronounced synergistic effect was manifested by stimulation of tumor progression and pathological changes in visceral organs, expanding our understanding of cancer pathogenesis in the presence of comorbid disease.
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2630
Antitumor and Antimetastatic Activity of a Novel Pyrimidin-4-one Derivative in the B16–F10 Melanoma Mouse Model: A Pilot Study
Введение. Меланома кожи характеризуется высоким метастатическим потенциалом. Участие EGFR в инвазии и прогрессировании меланомы обосновывает поиск новых EGFR-ориентированных антиметастатических подходов. Цель. Оценка влияния нового производного пиримидин-4-она (6MPSVan-Na) на рост, метастазирование и морфологию перевивной меланомы В16-F10. Материалы и методы. Эксперимент выполнен на самцах мышей C57BL/6 с подкожно трансплантированной меланомой В16–F10. Животные были распределены на три группы (по n = 10 в каждой): основная группа (6MPSVan-Na, 18,7 мг/кг внутримышечно); отрицательный контроль (вода для инъекций внутримышечно); группа гефитиниба (43,4 мг/кг перорально) как позитивный контроль чувствительности модели к ингибиторам тирозинкиназы EGFR. Воздействие проводили в течение пяти дней со дня перевивки, через два дня курс повторяли. Оценивали латентный период, динамику объема и торможения роста опухоли (ТРО %), продолжительность жизни, выживаемость (Kаплан — Майер), частоту макрометастазов. Проведен гистологический анализ опухолевой ткани. Статистическая обработка: критерии Манна — Уитни, точный критерий Фишера, log-rank-тест, ANOVA (уровень значимости α = 0,05). Результаты. Исследование выявило чувствительность меланомы В16-F10 к действию референтного препарат гефитиниба. Профиль противоопухолевой активности экспериментального соединения 6MPSVan-Na характеризовался торможением роста меланомы в постэкспозиционный период (ТРО % ≥ 50 %), статистически значимым увеличением продолжительности жизни мышей, снижением частоты выявления макрометастазов в легких до 20 %, в лимфоузлах — до 30 % (p < 0,05). После воздействия 6MPSVan-Na преимущественно определялись морфологические признаки некроптоза (обширный некроз, выраженная инфильтрация лимфоцитами и гистиоцитами, формирование лимфоцитарного вала и соединительнотканной капсулы). Заключение. В пилотном исследовании новое производное пиримидин-4-она продемонстрировало противоопухолевую и антиметастатическую активность в отношении меланомы В16-F10, реализующуюся, вероятно, через активацию некроптоза и стимуляцию опухолеспецифического иммунного ответа. Полученные данные обосновывают дальнейшее изучение 6MPSVan-Na в качестве потенциального антиметастатического агента при меланоме.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2630
Open AccessAntitumor and Antimetastatic Activity of a Novel Pyrimidin-4-one Derivative in the B16–F10 Melanoma Mouse Model: A Pilot Study
Введение. Меланома кожи характеризуется высоким метастатическим потенциалом. Участие EGFR в инвазии и прогрессировании меланомы обосновывает поиск новых EGFR-ориентированных антиметастатических подходов. Цель. Оценка влияния нового производного пиримидин-4-она (6MPSVan-Na) на рост, метастазирование и морфологию перевивной меланомы В16-F10. Материалы и методы. Эксперимент выполнен на самцах мышей C57BL/6 с подкожно трансплантированной меланомой В16–F10. Животные были распределены на три группы (по n = 10 в каждой): основная группа (6MPSVan-Na, 18,7 мг/кг внутримышечно); отрицательный контроль (вода для инъекций внутримышечно); группа гефитиниба (43,4 мг/кг перорально) как позитивный контроль чувствительности модели к ингибиторам тирозинкиназы EGFR. Воздействие проводили в течение пяти дней со дня перевивки, через два дня курс повторяли. Оценивали латентный период, динамику объема и торможения роста опухоли (ТРО %), продолжительность жизни, выживаемость (Kаплан — Майер), частоту макрометастазов. Проведен гистологический анализ опухолевой ткани. Статистическая обработка: критерии Манна — Уитни, точный критерий Фишера, log-rank-тест, ANOVA (уровень значимости α = 0,05). Результаты. Исследование выявило чувствительность меланомы В16-F10 к действию референтного препарат гефитиниба. Профиль противоопухолевой активности экспериментального соединения 6MPSVan-Na характеризовался торможением роста меланомы в постэкспозиционный период (ТРО % ≥ 50 %), статистически значимым увеличением продолжительности жизни мышей, снижением частоты выявления макрометастазов в легких до 20 %, в лимфоузлах — до 30 % (p < 0,05). После воздействия 6MPSVan-Na преимущественно определялись морфологические признаки некроптоза (обширный некроз, выраженная инфильтрация лимфоцитами и гистиоцитами, формирование лимфоцитарного вала и соединительнотканной капсулы). Заключение. В пилотном исследовании новое производное пиримидин-4-она продемонстрировало противоопухолевую и антиметастатическую активность в отношении меланомы В16-F10, реализующуюся, вероятно, через активацию некроптоза и стимуляцию опухолеспецифического иммунного ответа. Полученные данные обосновывают дальнейшее изучение 6MPSVan-Na в качестве потенциального антиметастатического агента при меланоме.
- Open Access
- 23 April 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (6) , 327-340
Features of insulin like growth factor levels in biological fluids and tumor tissue in patients with non muscle invasive bladder cancer and type 2 diabetes mellitus
Background: Non-muscle-invasive bladder cancer (NMIBC) is characterized by high prevalence and a high recurrence rate. Data on the association of type 2 diabetes mellitus (T2DM) with the risk and prognosis of bladder cancer are conflicting. Understanding the effect of comorbid T2DM on the insulin signaling system in NMIBC patients may improve the diagnostic work-up and optimize antitumor treatment. Aim: To identify differences in the levels of insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) in blood, urine and tumor tissue between patients with NMIBC and T2DM, patients with NMIBC without T2DM, patients with T2DM without cancer, and healthy controls (donors). Methods: This pilot single-center cross-sectional comparative study included 20 newly diagnosed NMIBC patients with comorbid T2DM (middle-aged and elderly) hospitalized from September 2022 to May 2024. IGF-1 and IGF-2 levels were measured by enzyme-linked immunosorbent assay in serum and urine samples collected before surgery, and in tumor tissue homogenates. The results were compared with those from 20 NMIBC patients without T2DM, 12 outpatients with T2DM without cancer, and 10 healthy donors examined during the same period. Blood glucose and glycated hemoglobin (HbA1c) levels were determined in all subjects. Results: In NMIBC patients with T2DM, the blood IGF-1 level did not exceed the median value of the donor group (589 ng/mL) in 18 out of 20 cases and was on average two-fold lower than in T2DM patients without cancer (p 0.001). In 25% (5/20) of NMIBC patients and 50% (6/12) of T2DM patients, the blood IGF-1 level exceeded the maximum donor value (998 ng/mL). Blood IGF-2 levels were higher in T2DM patients than in all other groups (p 0.001), whereas the other groups did not differ from each other. The NMIBC group showed the highest variability in circulating IGF-2 (coefficient of variation 273%) and included isolated cases with levels close to those observed in T2DM patients. Urinary IGF-1 excretion in NMIBC patients with T2DM did not differ from that in donors and was on average four-fold lower than in NMIBC patients without diabetes (p = 0.003). Tumor tissue IGF levels did not differ between patients with and without diabetes. In NMIBC patients with T2DM receiving metformin, a positive correlation was found between blood IGF-1 and glucose levels (Spearman’s rank correlation coefficient +0.803, p = 0.034), and their blood IGF-1 level was on average 1.7-fold lower than in other patients of this group (p = 0.047). In normoglycemic cases on metformin, the blood IGF-1 level was the lowest, on average 3.8-fold below donor values (p = 0.007). Conclusion: In middle-aged and elderly patients of both sexes with NMIBC and comorbid T2DM, in contrast to T2DM patients without cancer and NMIBC patients without T2DM, relatively low blood and urine IGF-1 and IGF-2 levels were observed, close to those in donors, and tumor IGFs levels did not differ from control values. In NMIBC patients with T2DM receiving metformin, unlike other patients and donors, a strong positive correlation between blood IGF-1 and glucose levels was found. In normoglycemic patients on metformin, the blood IGF-1 level was the lowest among all patients and donors. This may indicate a possible mechanism of the antitumor effect of metformin, but this observation requires confirmation in larger clinical studies.
- 23 April 2026
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (6) , 327-340
Open AccessFeatures of insulin like growth factor levels in biological fluids and tumor tissue in patients with non muscle invasive bladder cancer and type 2 diabetes mellitus
Background: Non-muscle-invasive bladder cancer (NMIBC) is characterized by high prevalence and a high recurrence rate. Data on the association of type 2 diabetes mellitus (T2DM) with the risk and prognosis of bladder cancer are conflicting. Understanding the effect of comorbid T2DM on the insulin signaling system in NMIBC patients may improve the diagnostic work-up and optimize antitumor treatment. Aim: To identify differences in the levels of insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) in blood, urine and tumor tissue between patients with NMIBC and T2DM, patients with NMIBC without T2DM, patients with T2DM without cancer, and healthy controls (donors). Methods: This pilot single-center cross-sectional comparative study included 20 newly diagnosed NMIBC patients with comorbid T2DM (middle-aged and elderly) hospitalized from September 2022 to May 2024. IGF-1 and IGF-2 levels were measured by enzyme-linked immunosorbent assay in serum and urine samples collected before surgery, and in tumor tissue homogenates. The results were compared with those from 20 NMIBC patients without T2DM, 12 outpatients with T2DM without cancer, and 10 healthy donors examined during the same period. Blood glucose and glycated hemoglobin (HbA1c) levels were determined in all subjects. Results: In NMIBC patients with T2DM, the blood IGF-1 level did not exceed the median value of the donor group (589 ng/mL) in 18 out of 20 cases and was on average two-fold lower than in T2DM patients without cancer (p 0.001). In 25% (5/20) of NMIBC patients and 50% (6/12) of T2DM patients, the blood IGF-1 level exceeded the maximum donor value (998 ng/mL). Blood IGF-2 levels were higher in T2DM patients than in all other groups (p 0.001), whereas the other groups did not differ from each other. The NMIBC group showed the highest variability in circulating IGF-2 (coefficient of variation 273%) and included isolated cases with levels close to those observed in T2DM patients. Urinary IGF-1 excretion in NMIBC patients with T2DM did not differ from that in donors and was on average four-fold lower than in NMIBC patients without diabetes (p = 0.003). Tumor tissue IGF levels did not differ between patients with and without diabetes. In NMIBC patients with T2DM receiving metformin, a positive correlation was found between blood IGF-1 and glucose levels (Spearman’s rank correlation coefficient +0.803, p = 0.034), and their blood IGF-1 level was on average 1.7-fold lower than in other patients of this group (p = 0.047). In normoglycemic cases on metformin, the blood IGF-1 level was the lowest, on average 3.8-fold below donor values (p = 0.007). Conclusion: In middle-aged and elderly patients of both sexes with NMIBC and comorbid T2DM, in contrast to T2DM patients without cancer and NMIBC patients without T2DM, relatively low blood and urine IGF-1 and IGF-2 levels were observed, close to those in donors, and tumor IGFs levels did not differ from control values. In NMIBC patients with T2DM receiving metformin, unlike other patients and donors, a strong positive correlation between blood IGF-1 and glucose levels was found. In normoglycemic patients on metformin, the blood IGF-1 level was the lowest among all patients and donors. This may indicate a possible mechanism of the antitumor effect of metformin, but this observation requires confirmation in larger clinical studies.
- Open Access
- 10 April 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (2) , 119-124
Effect of different variants of radiation treatment on the parameters of tissue plasminogen activator and its inhibitor in the blood of patients with metastatic brain lesions
Background. The prevalence of metastatic brain tumors (MBT), accompanied by high mortality and limited treatment options associated with the localization of the process, underscores the importance of studying the metabolic systems involved in the progression of malignant disease and sensitivity to antitumor treatment. One such system is the fibrinolytic system, which comprises a series of activators, inhibitors, and receptors. Aim. To examine the levels and activities of tissue plasminogen activator (tPA), as well as fibrinolysis inhibitor, in the blood of patients with MBT who are undergoing various radiotherapeutic treatments. Materials and methods. The activity and content of tPA and type 1 plasminogen activator inhibitor (PAI-1) were studied in the blood plasma of 38 patients with MBT by enzyme-linked immunosorbent assay. The results were compared with the data of 18 people without oncologic pathology (donor group). Three groups were formed according to the treatment options: Control group – stereotactic radiotherapy on the place of the removed metastasis with a single focal dose (SFD) of 6 Gy up to a total dose of 30 Gy; Main group No. 1 – after a session of preoperative radiosurgery with a SFD of 10–15 Gy, the metastatic focus was removed 24 hours later; Main group No. 2 – staged radiosurgery (SRS) was performed in 3 stages with a SFD of 10 Gy and an interval between sessions of 14 days (total 30 Gy). Results. For patients with metastatic brain lesions, before the start of treatment, a 2.1-fold increase in tPA activity was typical, with a 3.6-fold decrease in its content, leading to a 10-fold increase in their ratio. In the control group, tPA activity remained elevated 3 days after surgery, after a month it did not differ from the level in donors, and the tPA content was reduced. In both main groups, a heightened level of tPA activity was observed throughout the observation period. After one month, this activity was found to be 2.6 times higher compared to the control group (p≤0.001). Only patients receiving SRS were characterized by an increase in the initially decreased tPA content, accompanied by a shift towards normalization of the ratio of tPA activity to its content. This was concomitant with an increase in PAI-1 activity, reaching the donor level. Conclusion. The identified dynamics of tPA parameters may contribute to the clinical efficacy of SRS.
- 10 April 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (2) , 119-124
Open AccessEffect of different variants of radiation treatment on the parameters of tissue plasminogen activator and its inhibitor in the blood of patients with metastatic brain lesions
Background. The prevalence of metastatic brain tumors (MBT), accompanied by high mortality and limited treatment options associated with the localization of the process, underscores the importance of studying the metabolic systems involved in the progression of malignant disease and sensitivity to antitumor treatment. One such system is the fibrinolytic system, which comprises a series of activators, inhibitors, and receptors. Aim. To examine the levels and activities of tissue plasminogen activator (tPA), as well as fibrinolysis inhibitor, in the blood of patients with MBT who are undergoing various radiotherapeutic treatments. Materials and methods. The activity and content of tPA and type 1 plasminogen activator inhibitor (PAI-1) were studied in the blood plasma of 38 patients with MBT by enzyme-linked immunosorbent assay. The results were compared with the data of 18 people without oncologic pathology (donor group). Three groups were formed according to the treatment options: Control group – stereotactic radiotherapy on the place of the removed metastasis with a single focal dose (SFD) of 6 Gy up to a total dose of 30 Gy; Main group No. 1 – after a session of preoperative radiosurgery with a SFD of 10–15 Gy, the metastatic focus was removed 24 hours later; Main group No. 2 – staged radiosurgery (SRS) was performed in 3 stages with a SFD of 10 Gy and an interval between sessions of 14 days (total 30 Gy). Results. For patients with metastatic brain lesions, before the start of treatment, a 2.1-fold increase in tPA activity was typical, with a 3.6-fold decrease in its content, leading to a 10-fold increase in their ratio. In the control group, tPA activity remained elevated 3 days after surgery, after a month it did not differ from the level in donors, and the tPA content was reduced. In both main groups, a heightened level of tPA activity was observed throughout the observation period. After one month, this activity was found to be 2.6 times higher compared to the control group (p≤0.001). Only patients receiving SRS were characterized by an increase in the initially decreased tPA content, accompanied by a shift towards normalization of the ratio of tPA activity to its content. This was concomitant with an increase in PAI-1 activity, reaching the donor level. Conclusion. The identified dynamics of tPA parameters may contribute to the clinical efficacy of SRS.
- Open Access
- 13 March 2026
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 7 (1) , 24-38
The influence of radiation treatment options on the urokinase system of plasminogen activation in the blood of patients with metastatic brain lesions
Влияние вариантов лучевого лечения на урокиназную систему активации плазминогена в крови больных с метастатическим поражением головного мозга
- 13 March 2026
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 7 (1) , 24-38
Open AccessThe influence of radiation treatment options on the urokinase system of plasminogen activation in the blood of patients with metastatic brain lesions
Влияние вариантов лучевого лечения на урокиназную систему активации плазминогена в крови больных с метастатическим поражением головного мозга
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 6-15
The content of steroid hormones in the mitochondria of unchanged and tumor tissue of the uterine body
Mitochondria regulate a wide range of processes, including stress responses, metabolism, immunity, differentiation, redox homeostasis, and steroidogenesis, and also serve as the principal intracellular source of reactive oxygen species (ROS). Mitochondrial dysfunction has been linked to the development of various pathological conditions, including the growth of both benign and malignant tumors. Purpose of the study . Determination of the level of steroid hormones in the mitochondria of various tissues of the uterine body. Materials and methods . The study included 65 patients with benign and malignant diseases of the uterus: 25 patients with endometrioid adeno‑ carcinoma of the uterus (EAC) of low differentiation (G3) stage II–III; 15 patients with leiomyosarcoma of the uterus stage I–III; and 25 patients with uterine myoma. Mitochondria from native samples of uterine tumors were isolated by differential centrifugation in a high-speed refrigerated centrifuge Avanti J-E, Becman Coulter. For the comparison group, mitochondria were isolated from intact uterine tissue. The levels of estradiol (E2), testosterone (T), progesterone (P4), and cortisol were determined using standard ELISA kits (Monobind, USA) in mitochondria isolated from the indicated tissues. A statistical analysis of the results was conducted using the Statistica 10.0 software package. Results. Irrespective of the nature of the tumor process (benign or malignant), a decrease in the P4 level by 2.7 to 9.1 times, but an increase in the content of cortisol by 1.3 to 3.7 times and T by 2.1 to 3.7 times were detected in the mitochondria of uterine tumors. Conversely, the concentration of E2 in the mitochondria of uterine fibroids exhibited an increase of 2.2 times compared to the indicators in the mitochondria of the intact uterus. No significant differences were observed in the mitochondria of EAC, while a decrease of 1.4 times was noted in the mi‑ tochondria of uterine sarcoma. Conclusion . There is a change in the content of steroid hormones in In the mitochondria of uterine tumors, consisting in an increase in the concentrations of cortisol and testosterone and progesterone deficiency regardless of the type of pathology, but a relative or absolute defi‑ ciency of estrogens only in the mitochondria of malignant tumors. Changes in the steroid background of tumor mitochondria, compared with the mitochondria of the intact uterus, probably have a significant effect on both the energy balance of cells and the production of ROS, as well as on proliferative processes.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 6-15
The content of steroid hormones in the mitochondria of unchanged and tumor tissue of the uterine body
Mitochondria regulate a wide range of processes, including stress responses, metabolism, immunity, differentiation, redox homeostasis, and steroidogenesis, and also serve as the principal intracellular source of reactive oxygen species (ROS). Mitochondrial dysfunction has been linked to the development of various pathological conditions, including the growth of both benign and malignant tumors. Purpose of the study . Determination of the level of steroid hormones in the mitochondria of various tissues of the uterine body. Materials and methods . The study included 65 patients with benign and malignant diseases of the uterus: 25 patients with endometrioid adeno‑ carcinoma of the uterus (EAC) of low differentiation (G3) stage II–III; 15 patients with leiomyosarcoma of the uterus stage I–III; and 25 patients with uterine myoma. Mitochondria from native samples of uterine tumors were isolated by differential centrifugation in a high-speed refrigerated centrifuge Avanti J-E, Becman Coulter. For the comparison group, mitochondria were isolated from intact uterine tissue. The levels of estradiol (E2), testosterone (T), progesterone (P4), and cortisol were determined using standard ELISA kits (Monobind, USA) in mitochondria isolated from the indicated tissues. A statistical analysis of the results was conducted using the Statistica 10.0 software package. Results. Irrespective of the nature of the tumor process (benign or malignant), a decrease in the P4 level by 2.7 to 9.1 times, but an increase in the content of cortisol by 1.3 to 3.7 times and T by 2.1 to 3.7 times were detected in the mitochondria of uterine tumors. Conversely, the concentration of E2 in the mitochondria of uterine fibroids exhibited an increase of 2.2 times compared to the indicators in the mitochondria of the intact uterus. No significant differences were observed in the mitochondria of EAC, while a decrease of 1.4 times was noted in the mi‑ tochondria of uterine sarcoma. Conclusion . There is a change in the content of steroid hormones in In the mitochondria of uterine tumors, consisting in an increase in the concentrations of cortisol and testosterone and progesterone deficiency regardless of the type of pathology, but a relative or absolute defi‑ ciency of estrogens only in the mitochondria of malignant tumors. Changes in the steroid background of tumor mitochondria, compared with the mitochondria of the intact uterus, probably have a significant effect on both the energy balance of cells and the production of ROS, as well as on proliferative processes.
- Open Access
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 68-78
Study of the intensity of free radical oxidation in mitochondria of endometrioid adenocarcinoma cells depending on the degree of tumor differentiation
Purpose of the study . To investigate redox-balance parameters in mitochondria of endometrioid adenocarcinoma (EA) cells in oncogynecological patients, as well as in mitochondria of Guerin carcinoma cells with intramural tumor localization in rats. Materials and methods . The clinical part of the study included patients who underwent surgical treatment for EA (n = 42) and uterine fibroids (n = 14). Among patients with EA, 16 had well-differentiated tumors (G1), 12 had moderately differentiated tumors (G2), and 14 had poorly differentiated tumors (G3). The mean age of patients with EA was 60.8 ± 2.9 years, and with fibroids – 49.4 ± 2.5 years. None of the patients received neoadjuvant therapy. The experimental part of the study included biological material obtained from non-linear white female laboratory rats (n = 15) weighing 250 ± 25 g. Intramural growth of Guerin carcinoma was reproduced in these animals. In mitochondria isolated from EA, fibroid, and intact uterine tissues, concentrations of the following parameters were determined using standard ELISA methods: mitochondrial superoxide dismutase (SOD‑2), DNA and RNA oxidative modification products, malondialdehyde (MDA), diene conjugates (DC), and total protein (biuret method). Statistical analysis was performed using Statistica 10.0. Results . In women, mitochondria of EA cells in G1 tumors demonstrated a markedly elevated content of MDA and DC – 2.3‑fold and 2.9‑fold higher, respectively, compared with values in mitochondria of intact uterine tissue. In G2 tumors, MDA levels were 3.2‑fold higher and DC levels 2.7‑fold higher than in intact mitochondria. In G3 tumors, the degree of DNA damage increased 1.6‑fold (p < 0.05), while MDA, DC, and SOD‑2 concentrations increased 2.4‑fold, 3.0‑fold, and 3.4‑fold, respectively, compared with intact values. In female rats, mitochondria isolated from tumor tissues with intramural Guerin carcinoma growth displayed changes similar in direction to the clinical results: DNA damage increased 1.6‑fold (p < 0.05), MDA 1.6‑fold (p < 0.05), DC 1.5‑fold (p < 0.05), and SOD‑2 2.4‑fold. Conclusion . The oxidative stress and mitochondrial dysfunction identified in malignant cells of women indicate a differentiationdependent pathogenetic feature. Additionally, an identical direction of redox-balance alterations was demonstrated in the experimental subcellular model, supporting the translational relevance of the findings.
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 68-78
Open AccessStudy of the intensity of free radical oxidation in mitochondria of endometrioid adenocarcinoma cells depending on the degree of tumor differentiation
Purpose of the study . To investigate redox-balance parameters in mitochondria of endometrioid adenocarcinoma (EA) cells in oncogynecological patients, as well as in mitochondria of Guerin carcinoma cells with intramural tumor localization in rats. Materials and methods . The clinical part of the study included patients who underwent surgical treatment for EA (n = 42) and uterine fibroids (n = 14). Among patients with EA, 16 had well-differentiated tumors (G1), 12 had moderately differentiated tumors (G2), and 14 had poorly differentiated tumors (G3). The mean age of patients with EA was 60.8 ± 2.9 years, and with fibroids – 49.4 ± 2.5 years. None of the patients received neoadjuvant therapy. The experimental part of the study included biological material obtained from non-linear white female laboratory rats (n = 15) weighing 250 ± 25 g. Intramural growth of Guerin carcinoma was reproduced in these animals. In mitochondria isolated from EA, fibroid, and intact uterine tissues, concentrations of the following parameters were determined using standard ELISA methods: mitochondrial superoxide dismutase (SOD‑2), DNA and RNA oxidative modification products, malondialdehyde (MDA), diene conjugates (DC), and total protein (biuret method). Statistical analysis was performed using Statistica 10.0. Results . In women, mitochondria of EA cells in G1 tumors demonstrated a markedly elevated content of MDA and DC – 2.3‑fold and 2.9‑fold higher, respectively, compared with values in mitochondria of intact uterine tissue. In G2 tumors, MDA levels were 3.2‑fold higher and DC levels 2.7‑fold higher than in intact mitochondria. In G3 tumors, the degree of DNA damage increased 1.6‑fold (p < 0.05), while MDA, DC, and SOD‑2 concentrations increased 2.4‑fold, 3.0‑fold, and 3.4‑fold, respectively, compared with intact values. In female rats, mitochondria isolated from tumor tissues with intramural Guerin carcinoma growth displayed changes similar in direction to the clinical results: DNA damage increased 1.6‑fold (p < 0.05), MDA 1.6‑fold (p < 0.05), DC 1.5‑fold (p < 0.05), and SOD‑2 2.4‑fold. Conclusion . The oxidative stress and mitochondrial dysfunction identified in malignant cells of women indicate a differentiationdependent pathogenetic feature. Additionally, an identical direction of redox-balance alterations was demonstrated in the experimental subcellular model, supporting the translational relevance of the findings.
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 96-112
Epidermal growth factor receptor blockers – known possibilities and new perspectives in oncology
The epidermal growth factor receptor (EGFR) is a critical signaling molecule that, upon activation, promotes neoplastic transformation and metastasis. The utilization of targeted drugs, specifically EGFR inhibitors, has emerged as a pivotal component in the management of diverse malignant neoplasms. Among them, low-molecular-weight heterocyclic compounds acting as blockers of the EGFR tyrosine kinase domain occupy a key position. Purpose of the study . Is to conduct analysis of modern literature data devoted to the development and study of the antitumor acttivity of small molecule EGFR inhibitors, with a focus on blockers of the receptor’s intracellular domain. Materials and methods . A comprehensive literature search was conducted in the PubMed and eLibrary databases. The following keywords were entered into the search engine: "EGFR inhibitors", "small molecular weight kinase inhibitors" (SMKIs), "antitumor effect", "pyrimidine derivatives", "molecular docking", and "molecular modeling". Original research articles, meta-analyses, randomized controlled trials, and systematic reviews published predominantly published within the last five years. Results . The review presents the main characteristics of small molecule EGFR inhibitors, their mechanisms of action, and classification. The present study explores the underlying causes of resistance to targeted drugs aimed at the internal domain of the receptor, as well as the available strategies for overcoming such drug resistance. The subsequent sections of this text will discuss the development of new EGFR blockers, strategies for increasing their selectivity and efficacy, including through bioinformatic approaches. Conclusion . Currently, a significant amount of data has been accumulated on the development and use of small molecule heterocyclic EGFR tyrosine kinase inhibitors in the treatment of cancer patients. The main reasons limiting their use in clinical practice are the emergence of resistance due to receptor mutations and toxicity. In this regard, the search for new candidate compounds with a putative antitumor mechanism of action and high affinity to the target remains relevant. Inhibitory activity against the internal domain of EGFR directly depends on the structure of the heterocycle underlying the drug, which must be taken into account when creating new molecules that block this receptor. An important role in this process is played by computer modeling, which allows for a significant reduction in material costs and time. The presented review can be useful for researchers developing domestic targeted drugs aimed at the internal domain of EGFR, as part of import substitution to ensure the technological sovereignty of the Russian Federation.
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 96-112
Epidermal growth factor receptor blockers – known possibilities and new perspectives in oncology
The epidermal growth factor receptor (EGFR) is a critical signaling molecule that, upon activation, promotes neoplastic transformation and metastasis. The utilization of targeted drugs, specifically EGFR inhibitors, has emerged as a pivotal component in the management of diverse malignant neoplasms. Among them, low-molecular-weight heterocyclic compounds acting as blockers of the EGFR tyrosine kinase domain occupy a key position. Purpose of the study . Is to conduct analysis of modern literature data devoted to the development and study of the antitumor acttivity of small molecule EGFR inhibitors, with a focus on blockers of the receptor’s intracellular domain. Materials and methods . A comprehensive literature search was conducted in the PubMed and eLibrary databases. The following keywords were entered into the search engine: "EGFR inhibitors", "small molecular weight kinase inhibitors" (SMKIs), "antitumor effect", "pyrimidine derivatives", "molecular docking", and "molecular modeling". Original research articles, meta-analyses, randomized controlled trials, and systematic reviews published predominantly published within the last five years. Results . The review presents the main characteristics of small molecule EGFR inhibitors, their mechanisms of action, and classification. The present study explores the underlying causes of resistance to targeted drugs aimed at the internal domain of the receptor, as well as the available strategies for overcoming such drug resistance. The subsequent sections of this text will discuss the development of new EGFR blockers, strategies for increasing their selectivity and efficacy, including through bioinformatic approaches. Conclusion . Currently, a significant amount of data has been accumulated on the development and use of small molecule heterocyclic EGFR tyrosine kinase inhibitors in the treatment of cancer patients. The main reasons limiting their use in clinical practice are the emergence of resistance due to receptor mutations and toxicity. In this regard, the search for new candidate compounds with a putative antitumor mechanism of action and high affinity to the target remains relevant. Inhibitory activity against the internal domain of EGFR directly depends on the structure of the heterocycle underlying the drug, which must be taken into account when creating new molecules that block this receptor. An important role in this process is played by computer modeling, which allows for a significant reduction in material costs and time. The presented review can be useful for researchers developing domestic targeted drugs aimed at the internal domain of EGFR, as part of import substitution to ensure the technological sovereignty of the Russian Federation.
- Open Access
- 9 September 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (3) , 63-76
Lymph nodes as a target for the use of dendritic cell vaccines: modern approaches and prospects
This article provides an overview of current approaches to cancer immunotherapy, with an emphasis on the role of dendritic cells (DCs), lymph nodes (LNs), and innovative methods of vaccine delivery. Immunotherapy using DC-based vaccines represents a promising direction, capable of stimulating a specific immune response against tumor cells and forming long-term immune memory. Tumor-draining lymph nodes (TDLNs) play a key role in immune activation, as they are the sites where dendritic cells present tumor antigens and activate T-cells. In cancer, unlike viral infections, CD8+ T-cell activation occurs in two stages, and the effectiveness of this process depends on signals from the tumor microenvironment, which explains why the immune response to cancer is often weak.The article also discusses modern strategies for delivering vaccines to lymph nodes, including the use of nanoparticles, bioorthogonal reactions, and photothermally induced materials. These approaches help overcome the "granularity paradox", associated with the need to balance vaccine size for LN penetration and uptake by immune cells. The prospects of adoptive cell therapy using T-cells from TDLNs, as well as the role of exosomes and whole-cell tumor antigens in the development of effective vaccines, are also considered. Combination strategies, such as the use of vaccines together with checkpoint inhibitors (e. g., anti-PD1), demonstrate potential for enhancing antitumor immunity.The further advancement of cancer immunotherapy requires the integration of new knowledge about the biology of dendritic cells, modern methods of cell engineering, and nanotechnology to create personalized and effective antitumor vaccines.
- 9 September 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (3) , 63-76
Open AccessLymph nodes as a target for the use of dendritic cell vaccines: modern approaches and prospects
This article provides an overview of current approaches to cancer immunotherapy, with an emphasis on the role of dendritic cells (DCs), lymph nodes (LNs), and innovative methods of vaccine delivery. Immunotherapy using DC-based vaccines represents a promising direction, capable of stimulating a specific immune response against tumor cells and forming long-term immune memory. Tumor-draining lymph nodes (TDLNs) play a key role in immune activation, as they are the sites where dendritic cells present tumor antigens and activate T-cells. In cancer, unlike viral infections, CD8+ T-cell activation occurs in two stages, and the effectiveness of this process depends on signals from the tumor microenvironment, which explains why the immune response to cancer is often weak.The article also discusses modern strategies for delivering vaccines to lymph nodes, including the use of nanoparticles, bioorthogonal reactions, and photothermally induced materials. These approaches help overcome the "granularity paradox", associated with the need to balance vaccine size for LN penetration and uptake by immune cells. The prospects of adoptive cell therapy using T-cells from TDLNs, as well as the role of exosomes and whole-cell tumor antigens in the development of effective vaccines, are also considered. Combination strategies, such as the use of vaccines together with checkpoint inhibitors (e. g., anti-PD1), demonstrate potential for enhancing antitumor immunity.The further advancement of cancer immunotherapy requires the integration of new knowledge about the biology of dendritic cells, modern methods of cell engineering, and nanotechnology to create personalized and effective antitumor vaccines.
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 48-55
Type 2 diabetes mellitus and non-muscle invasive bladder cancer: characteristics of the epidermal growth factor system components content in blood, urine, and tumor
Background. The incidence of bladder cancer (BC) and type 2 diabetes mellitus (T2DM) are rising consistently worldwide. It is not uncommon for these two pathologies to be found in combination. T2DM is a contributing factor in many cancer types. It is currently understood that the development of non-muscle invasive BC (NMIBC) occurs primarily through the activation of oncogenes that involve the epidermal growth factor (EGF) system. However, the effect of T2DM on the EGF system in the context of NMIBC remains unclear.Aim. To investigate the specific content of the EGF system components in the blood, urine, and tumor tissue of patients with NMIBC with concomitant T2DM.Materials and methods. The participants were divided into the main group – patients with NMIBC and T2DM (n = 11), and the control group – patients with NMIBC without T2DM (n = 11). The comparison group comprised of patients with T2DM only (n = 8). All parameters were evaluated in comparison to those of healthy donors (n = 12). The levels of EGF (Ray Bio, Germany) and its soluble receptor (sEGFR) (RAD Systems, USA) were quantified in blood, urine and 10 % tumor tissue homogenates using standard EIA kits on an automatic analyzer, the Infinite F50 (Tecan Austria GmbH, Austria).Results. In 80 % of control group patients, blood EGF levels increased 2.8-fold compared to donors, while in 20 % they remained unchanged. Blood EGF content in patients with comorbid pathology and the comparison group (T2DM only) was comparable and at the same time 2.1–2.7 times lower than in most patients from the control group. In all BC patients, blood sEGFR concentration was 1.4 times lower than in donors and T2DM patients, but increased in urine: 2.9-fold in BC patients without T2DM and 3.5-fold in BC patients with T2DM. Patients with NMIBC and T2DM had 1.5 times less EGF and 2.0 times less sEGFR than NMIBC patients without T2DM.Conclusion. The patients with NMIBC and T2DM were deficient in EGF (in blood, urine, and tumor tissue) and sEGFR (in blood and tumor tissue), compared to the patients with NMIBC without T2DM who demonstrated increased levels of EGF (in blood, urine, and tumor tissue). The development of NMIBC was associated with an increase in urinary sEGFR concentrations, irrespective of T2DM status.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 48-55
Open AccessType 2 diabetes mellitus and non-muscle invasive bladder cancer: characteristics of the epidermal growth factor system components content in blood, urine, and tumor
Background. The incidence of bladder cancer (BC) and type 2 diabetes mellitus (T2DM) are rising consistently worldwide. It is not uncommon for these two pathologies to be found in combination. T2DM is a contributing factor in many cancer types. It is currently understood that the development of non-muscle invasive BC (NMIBC) occurs primarily through the activation of oncogenes that involve the epidermal growth factor (EGF) system. However, the effect of T2DM on the EGF system in the context of NMIBC remains unclear.Aim. To investigate the specific content of the EGF system components in the blood, urine, and tumor tissue of patients with NMIBC with concomitant T2DM.Materials and methods. The participants were divided into the main group – patients with NMIBC and T2DM (n = 11), and the control group – patients with NMIBC without T2DM (n = 11). The comparison group comprised of patients with T2DM only (n = 8). All parameters were evaluated in comparison to those of healthy donors (n = 12). The levels of EGF (Ray Bio, Germany) and its soluble receptor (sEGFR) (RAD Systems, USA) were quantified in blood, urine and 10 % tumor tissue homogenates using standard EIA kits on an automatic analyzer, the Infinite F50 (Tecan Austria GmbH, Austria).Results. In 80 % of control group patients, blood EGF levels increased 2.8-fold compared to donors, while in 20 % they remained unchanged. Blood EGF content in patients with comorbid pathology and the comparison group (T2DM only) was comparable and at the same time 2.1–2.7 times lower than in most patients from the control group. In all BC patients, blood sEGFR concentration was 1.4 times lower than in donors and T2DM patients, but increased in urine: 2.9-fold in BC patients without T2DM and 3.5-fold in BC patients with T2DM. Patients with NMIBC and T2DM had 1.5 times less EGF and 2.0 times less sEGFR than NMIBC patients without T2DM.Conclusion. The patients with NMIBC and T2DM were deficient in EGF (in blood, urine, and tumor tissue) and sEGFR (in blood and tumor tissue), compared to the patients with NMIBC without T2DM who demonstrated increased levels of EGF (in blood, urine, and tumor tissue). The development of NMIBC was associated with an increase in urinary sEGFR concentrations, irrespective of T2DM status.